Clinical Trial Update: Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma [Phase 3]

View source ↗

Summary

This is a Phase 3 trial update evaluating pemetrexed combined with gefitinib as adjuvant therapy for EGFR-mutant lung adenocarcinoma. The trial status is listed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Iressa (gefitinib)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Lung Neoplasms | Phase 3 | Status: UNKNOWN